In a melanoma model, HIF−1α inhibition was also shown to increase the accumulation of natural killer (NK) cells and CTLs in the tumor bed by upregulating chemokines such as CCL2 and CCL5, thereby enhancing the effectiveness of anti−PD−1 therapy and peptide vaccines (60). The gene discussed is CCL5; the disease is melanoma.